Doximity Inc. (DOCS)
NYSE NYSE Primary 
XSTU 
Doximity Rides on Telehealth Demand: Will This Drive Sales Further?
DOCS posts strong Q4 revenue growth and record user engagement as demand for telehealth and AI tools hits new highs.
Dr Martens interims a first test for new CEO after shares stumble to all-time low
Dr Martens PLC (LSE:DOCS) shares stumbled to a new all-time low below 50p last month after the US tariff announcement, but have been tiptoeing higher in the run-up to interim results due next Thursday, 5 June. Back in January, the boot-maker flagged "good progress" in its turnaround after revenue ticked up 3% on a constant currency basis during the third quarter, aided by stronger American and Asia Pacific sales, offsetting a decline in Europe due to strong promotional activity from rivals in December.
Doximity Stock Plunges Despite Q4 Earnings & Sales Beat, Margins Up
DOCS reports robust growth in unique active users and sales of workflow tools, driving the top and bottom lines. First-quarter fiscal 2026 sales outlook below estimates.
Doximity, Inc. (DOCS) Q4 2025 Earnings Call Transcript
Doximity, Inc. (NYSE:DOCS ) Q4 2025 Earnings Conference Call May 15, 2025 5:00 PM ET Company Participants Perry Gold - Head of IR Jeff Tangney - Co-Founder and CEO Anna Bryson - CFO Nate Gross - Co-Founder and CSO Conference Call Participants Brian Peterson - Raymond James Michael Cherny - Leerink Partners Elizabeth Anderson - Evercore ISI Ryan MacDonald - Needham Jared Haase - William Blair Allen Lutz - Bank of America Scott Schoenhaus - KeyBanc Ann Samuel - JPMorgan Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler Steven Veliquette - Mizuho Securities Jeff Garro - Stephens David Roman - Goldman Sachs Jailendra Singh - Truist Craig Hettenbach - Morgan Stanley Operator Good day, everyone, and welcome to the Doximity Q4 2025 Earnings Call. At this time, I will hand the call over to Perry Gold, Head of IR.
Doximity (DOCS) Surpasses Q4 Earnings and Revenue Estimates
Doximity (DOCS) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.25 per share a year ago.
Doximity Stock Drops 20% After Outlook Disappoints
Shares of Doximity plummeted late Thursday after the telehealth software company dished out a disappointing outlook.
Doximity Q4 Earnings Likely to Reflect Strong Product Momentum
Doximity's Q4 performance likely witnessed strong product-driven gains from new modules and integrated programs, though early revenue pull-forward might have tempered sequential growth.
Doximity (DOCS) Ascends But Remains Behind Market: Some Facts to Note
In the closing of the recent trading day, Doximity (DOCS) stood at $56.65, denoting a +0.64% change from the preceding trading day.
Tempus AI vs. Doximity: Which AI in Healthcare Stock is a Better Buy?
Both TEM and DOCS are technology-intensive healthcare companies leveraging artificial intelligence to enhance their platforms. Which one is a better investment?
Doximity (DOCS) Falls More Steeply Than Broader Market: What Investors Need to Know
Doximity (DOCS) closed at $60.55 in the latest trading session, marking a -1.51% move from the prior day.
Doximity (DOCS) Beats Stock Market Upswing: What Investors Need to Know
The latest trading day saw Doximity (DOCS) settling at $62.99, representing a +0.35% change from its previous close.
Buy These 5 Top-Ranked Stocks to Play Likely Earnings Beat
Top-ranked stocks Doximity (DOCS), Life Time Group Holdings (LTH), Adtalem Global Education (ATGE), BioMarin Pharmaceutical (BMRN) and Iridium Communications (IRDM) are likely to beat on the bottom line in their upcoming releases.
